Ocugen, Inc. has announced the commencement of its Phase 1 clinical trial for OCU200, targeting diabetic macular edema (DME). The trial, which has begun dosing its first patient, aims to evaluate ...

On Thursday, Ocugen Inc (OCGN) stock saw a decline, ending the day at $0.71 which represents a decrease of $-0.02 or -2.74% from the prior close of $0.73. The stock opened at $0.74 and touched a low ...

Armed with new data from its development partner Bharat Biotech, Ocugen is planning to press ... according to a preprint posted on the MedRxiv website, where studies can be published before ...

Ocugen released the data as part of its recent Clinical Showcase presentation, which is also posted on its website, according to a statement.

In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Ocugen (OCGN – Research Report), with a price target of $7.00. Discover outperforming stocks ...

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410 ...

On Tuesday, Ocugen Inc (OCGN) stock saw a decline, ending the day at $0.73 which represents a decrease of $-0.02 or -2.67% from the prior close of $0.75. The stock opened at $0.75 and touched a low of ...

Shares of Ocugen Inc. OCGN rallied 1.78% to $0.77 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average DJIA rising 0.04% ...

MALVERN, Pa., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering ...